blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3356370

EP3356370 - 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.06.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  16.07.2021
FormerGrant of patent is intended
Status updated on  15.03.2021
FormerExamination is in progress
Status updated on  28.03.2020
FormerRequest for examination was made
Status updated on  06.07.2018
FormerThe international publication has been made
Status updated on  08.04.2017
Formerunknown
Status updated on  04.11.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Siteone Therapeutics, Inc.
203 Enterprise Blvd., Suite 3
Bozeman MT 59718 / US
For all designated states
The Board of Trustees of the Leland Stanford Junior University
Office of the General Counsel
Building 170, Third Floor, Main Quad
P.O. Box 20386
Stanford, CA 94305-2038 / US
[2019/38]
Former [2018/32]For all designated states
Siteone Therapeutics, Inc.
203 Enterprise Blvd., Suite 3
Bozeman MT 59718 / US
For all designated states
The Board of Trustees of the Leland Stanford Junior University
Office of the General Counsel
Building 170, 3rd Floor, Main Quad
P.O. Box 20386
Stanford, CA 94305-2038 / US
Inventor(s)01 / MULCAHY, John
203 Enterprise Blvd.
Suite 3
Bozeman, Montana 59718 / US
02 / PAJOUHESH, Hassan
203 Enterprise Blvd.
Suite 3
Bozeman, Montana 59718 / US
03 / SHIBUYA, Grant Masaaki
203 Enterprise Blvd.
Suite 3
Bozeman, Montana 59718 / US
04 / DELWIG, Anton
203 Enterprise Blvd.
Suite 3
Bozeman, Montana 59718 / US
05 / DUBOIS, Justin
203 Enterprise Blvd.
Suite 3
Bozeman, Montana 59718 / US
 [2018/32]
Representative(s)Petty, Catrin Helen, et al
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
[2018/32]
Application number, filing date16785597.230.09.2016
[2018/32]
WO2016US55050
Priority number, dateUS201562235412P30.09.2015         Original published format: US 201562235412 P
[2018/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017059385
Date:06.04.2017
Language:EN
[2017/14]
Type: A1 Application with search report 
No.:EP3356370
Date:08.08.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 06.04.2017 takes the place of the publication of the European patent application.
[2018/32]
Type: B1 Patent specification 
No.:EP3356370
Date:18.08.2021
Language:EN
[2021/33]
Search report(s)International search report - published on:EP06.04.2017
ClassificationIPC:C07D487/14, A61K31/519, A61P25/00
[2018/32]
CPC:
C07D487/14 (EP,US); A61P15/00 (EP); A61P19/02 (EP);
A61P21/02 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P25/16 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/22 (EP); A61P27/06 (EP); A61P29/02 (EP);
A61P43/00 (EP); A61P9/10 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/32]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:11,13-MODIFIZIERTE SAXITOXINE ZUR BEHANDLUNG VON SCHMERZEN[2018/32]
English:11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN[2018/32]
French:SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR[2018/32]
Entry into regional phase10.04.2018National basic fee paid 
10.04.2018Designation fee(s) paid 
10.04.2018Examination fee paid 
Examination procedure10.04.2018Examination requested  [2018/32]
10.04.2018Date on which the examining division has become responsible
13.12.2018Amendment by applicant (claims and/or description)
01.04.2020Despatch of a communication from the examining division (Time limit: M06)
07.10.2020Reply to a communication from the examining division
16.03.2021Communication of intention to grant the patent
09.07.2021Fee for grant paid
09.07.2021Fee for publishing/printing paid
09.07.2021Receipt of the translation of the claim(s)
Opposition(s)19.05.2022No opposition filed within time limit [2022/30]
Fees paidRenewal fee
27.09.2018Renewal fee patent year 03
27.09.2019Renewal fee patent year 04
28.09.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.09.2016
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
MT18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
[2024/42]
Former [2024/22]HU30.09.2016
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2023/33]HU30.09.2016
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2023/30]AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/36]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/35]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
IE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/34]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BE30.09.2021
LU30.09.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/27]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/25]AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/24]AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/21]AT18.08.2021
DK18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/16]AT18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/10]AT18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/09]AT18.08.2021
FI18.08.2021
LT18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
PT20.12.2021
Former [2022/08]AT18.08.2021
FI18.08.2021
LT18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
Former [2022/07]AT18.08.2021
LT18.08.2021
NO18.11.2021
Cited inInternational search[I]WO2010129864  (UNIV LELAND STANFORD JUNIOR [US], et al) [I] 1-26 * claim 1 *;
 [A]WO2011098539  (PHYTOTOX LTD, et al) [A] 1-26* claim 1 *;
 [A]  - TAKAFUMI AKIMOTO ET AL, "Synthesis of saxitoxin derivatives bearing guanidine and urea groups at C13 and evaluation of their inhibitory activity on voltage-gated sodium channels", ORGANIC & BIOMOLECULAR CHEMISTRY, GB, (20130101), vol. 11, no. 38, doi:10.1039/c3ob41398e, ISSN 1477-0520, page 6642, XP055318484 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1039/c3ob41398e
 [A]  - TORU NISHIKAWA ET AL, "Synthesis of an Advanced Model of Zetekitoxin AB Focusing on the N -Acylisoxazolidine Amide Structure Corresponding to C13-C17", ASIAN JOURNAL OF ORGANIC CHEMISTRY , 1(2), 160-165 CODEN: AJOCC7; ISSN: 2193-5807, Germany, (20141023), vol. 3, no. 12, doi:10.1002/ajoc.201402206, ISSN 2193-5807, pages 1308 - 1311, XP055318510 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1002/ajoc.201402206
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US5059595
 US5073543
 US5120548
 US5354556
 US5591767
 US5639476
 US5639480
 US5674533
 US5733566
 US5739108
 US5891474
 US5922356
 US5972891
 US5980945
 US5993855
 US6045830
 US6087324
 US6113943
 US6197350
 US6248363
 US6264970
 US6267981
 US6376461
 US6419961
 US6589548
 US6613358
 US6699500
 US2010284913
    - OGATA ET AL., JPN. J. PHARMACOL., (2002), vol. 88, no. 4, pages 365 - 77
    - MOMIN ET AL., CURR OPIN NEUROBIOL., (2008), vol. 18, no. 4, pages 383 - 8
    - RUSH ET AL., J. PHYSIOL., (2007), vol. 579, pages 1 - 14
    - COX ET AL., NATURE, (2006), vol. 444, no. 7121, pages 894 - 898
    - LIJINSKY, FOOD COSMET. TOXICOL., (1982), vol. 20, page 393
    - LIJINSKY, J. NAT. CANCER INST., (1982), vol. 69, page 1127
    - MANGOLD, MUTATION RES., (1994), vol. 308, page 33
    - GORDON, DRUG METAB. DISPOS., (1987), vol. 15, page 589
    - ZELLO, METABOLISM, (1994), vol. 43, page 487
    - GATELY, J. NUCL. MED., (1986), vol. 27, page 388
    - WADE D, CHEM. BIOL. INTERACT., (1999), vol. 117, page 191
    - FOSTER ET AL., ADV. DRUG RES., (1985), vol. 14, pages 1 - 36
    - KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL., (1999), vol. 77, pages 79 - 88
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, MARCEL DEKKER, NEW YORK, (1995), page 379 80
    - SEFTON, CRC CRIT. REF. BIOMED. ENG., (1987), vol. 14, page 201
    - BUCHWALD ET AL., SURGERY, (1980), vol. 88, page 507
    - SAUDEK ET AL., N. ENGL. J. MED., (1989), vol. 321, page 574
    - GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, (1984), vol. 2, pages 115 - 138
    - LANGER, SCIENCE, (1990), vol. 249, pages 1527 - 1533
    - MORAN O; PICOLLO A; CONTI F, "Tonic and phasic guanidinium toxin-block of skeletal muscle Na channels expressed in Mammalian cells", BIOPHYS J, (2003), vol. 84, no. 5, doi:doi:10.1016/S0006-3495(03)70026-5, pages 2999 - 3006, XP029291930

DOI:   http://dx.doi.org/10.1016/S0006-3495(03)70026-5
    - FLEMING JJ; MCREYNOLDS MD; DU BOIS J, "+)-saxitoxin: a first and second generation stereoselective synthesis", JAM CHEM SOC., (2007), vol. 129, no. 32, doi:doi:10.1021/ja071501o, pages 9964 - 9975, XP055034206

DOI:   http://dx.doi.org/10.1021/ja071501o
    - MULCAHY JV; DU BOIS J, "A stereoselective synthesis of (+)-gonyautoxin 3", JAM CHEM SOC., (2008), vol. 130, pages 12630 - 12631
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.